Latest & greatest articles for gabapentin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on gabapentin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on gabapentin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for gabapentin

1. Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy

Pregabalin (Lyrica or other brands) and gabapentin (Neurontin or other brands): known dangers and uncertainties during pregnancy Prescrire IN ENGLISH - Spotlight ''Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy'', 1 May 2020 {1} {1} {1} | | > > > Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregabalin (Lyrica° or other brands) and gabapentin (Neurontin° or other brands): known dangers and uncertainties during pregnancy Taken during pregnancy, pregabalin and gabapentin expose the newborn to harmful effects. Pregabalin and gabapentin are two very similar drugs which are widely used in France, particularly as antiepileptics and to treat

2020 Prescrire

2. Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April

Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April As of 1 April 2019, pregabalin and gabapentin are controlled under the Misuse (...) of Drugs Act 1971 as Class C substances and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing pregabalin and gabapentin and observe patients for development of signs of abuse and dependence. Published 16 April 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: to reflect growing concern about abuse, both pregabalin and gabapentin are now classified as Class C controlled substances

2019 MHRA Drug Safety Update

3. Gabapentin for Adults with Neuropathic Pain

Gabapentin for Adults with Neuropathic Pain Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Efficacy

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

4. Gabapentin

Gabapentin Top results for gabapentin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for gabapentin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

5. Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults WIth Chronic Sciatica: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults WIth Chronic Sciatica: A Randomized Clinical Trial. Optimal pharmacologic treatment for chronic sciatica (CS) is currently unclear. While gabapentin (GBP) and pregabalin (PGB) are both used to treat CS, equipoise exists. Nevertheless, pharmaceutical regulation authorities typically subsidize one drug over the other. This hinders interchange wherever the favored drug is either ineffective or ill-tolerated.To assess GBP vs PGB head (...) of 57 (16.5) years. A third of the cohort were smokers (5 [28%]), and more than half consumed alcohol (12 [67%]). Gabapentin was superior to PGB, with fewer and less severe adverse events. Both GBP (mean [SD], 7.54 [1.39] to 5.82 [1.72]; P < .001) and PGB (mean [SD], 7.33 [1.30] to 6.38 [1.88]; P = .002) displayed significant visual analog pain intensity scale reduction and Oswestry Disability Index reduction (mean [SD], 59.22 [16.88] to 48.54 [15.52]; P < .001 for both). Head to head, GBP showed

2018 JAMA neurology Controlled trial quality: predicted high

6. Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis

Efficacy of Gabapentin versus Lorazepam in alcohol withdrawal syndrome: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

7. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

8. Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014

Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 | CADTH.ca Find the information you need Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 Narcotics, Benzodiazepines, Stimulants, and Gabapentin: Policies, Initiatives, and Practices Across Canada, 2014 (...) , as well as place a significant burden on our health, social services, and public safety systems.” 1 The purpose of this Environmental Scan is to provide an overview of policies, practices, and initiatives which the publicly funded drug programs, colleges of physicians and surgeons, and colleges of pharmacy are implementing across Canada to address the misuse, abuse, and diversion of prescription narcotics (opioids), benzodiazepines, stimulants, and gabapentin. This information may assist drug policy

2015 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

9. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial

Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation JAMA Intern Med Actions . 2020 Mar 9;e200249. doi: 10.1001/jamainternmed.2020.0249. Online ahead of print. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial , , , , , , Affiliations Expand Affiliation 1 Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South

2020 EvidenceUpdates

10. Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness

Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Gabapentin for Adults with Neuropathic Pain: A Review of the Clinical Effectiveness Last updated: March 12, 2018 Project Number: RC0970-000 Product Line: Research Type: Drug Report Type: Summary (...) with Critical Appraisal Result type: Report Question What is the clinical effectiveness of gabapentin for adults with neuropathic pain? Key Message The findings from four systematic reviews and one RCT for gabapentin (GBP) compared to placebo or active comparators is limited by quantity and quality of evidence for studies on neuropathic pain associated with conditions including chronic lower back pain, fibromyalgia, mixed neuropathic pain, and nerve injury pain. While some studies reported little

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Full Text available with Trip Pro

Effect of Perioperative Gabapentin on Postoperative Pain Resolution and Opioid Cessation in a Mixed Surgical Cohort: A Randomized Clinical Trial Guidelines recommend using gabapentin to decrease postoperative pain and opioid use, but significant variation exists in clinical practice.To determine the effect of perioperative gabapentin on remote postoperative time to pain resolution and opioid cessation.A randomized, double-blind, placebo-controlled trial of perioperative gabapentin was conducted (...) of participants with continued pain or opioid use at 6 months and 1 year.Of 1805 patients screened for enrollment, 1383 were excluded, including 926 who did not meet inclusion criteria and 273 who declined to participate. Overall, 8% of patients randomized were lost to follow-up. A total of 202 patients were randomized to active placebo and 208 patients were randomized to gabapentin in the intention-to-treat analysis (mean [SD] age, 56.7 [11.7] years; 256 (62.4%) women and 154 (37.6%) men). Baseline

2018 EvidenceUpdates

12. Treatment for Alcohol Dependence With Gabapentin

Treatment for Alcohol Dependence With Gabapentin Treatment for Alcohol Dependence With Gabapentin - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment for Alcohol Dependence With Gabapentin (TAG (...) for this population of patients. Gabapentin is Food and Drug Administration-approved for the management of epileptic seizures and neuropathic pain. It is believed to act by blocking a specific alpha-2d subunit of the voltage-gated calcium channel at selective presynaptic sites and, as a result, to indirectly modulate Gamma Butyric Acid neurotransmission. Pre-clinical findings indicate that gabapentin normalizes the stress-induced Gamma Butyric Acid activation in the amygdala that is associated with alcohol

2016 Clinical Trials

13. Gabapentin and pregabalin: major adverse effects

Gabapentin and pregabalin: major adverse effects Prescrire IN ENGLISH - Spotlight ''Gabapentin and pregabalin: major adverse effects'', 1 November 2014 {1} {1} {1} | | > > > Gabapentin and pregabalin: major adverse effects Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Gabapentin and pregabalin: major adverse effects To reduce the consequences (...) of some severe adverse effects associated with gabapentin or pregabalin, it is advisable not to expose patients to them other than in situations where these drugs have proved to be highly effective. Gabapentin and pregabalin are used in certain epilepsies and for pain in neurological diseases. Pregabalin is also used to treat anxiety disorders. According to a review of French pharmacovigilance data published in 2013, between 1995 and 2009, 2415 adverse effects linked to gabapentin or pregabalin were

2014 Prescrire

14. Gabapentin and pregabalin: Are high doses justified?

Gabapentin and pregabalin: Are high doses justified? Gabapentin and pregabalin: Are high doses justified? January 2019 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: 604 822 0700 Fax: 604 822 0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 117 A nalgesia once seemed a relatively straightfor- ward aspect of medicine. Recommendations in textbooks (...) and guidelines were definitive, albeit heavily conflicted. Even recent guidelines encourage dose titration, based on an implicit, if unsupported, notion that more is likely to be better. 1 Recent experiments and systematic reviews show that drugs seldom outperform placebo significantly in chronic pain. Even old standards like acetaminophen and amitriptyline do not stand up well to careful scru- tiny of randomized placebo-controlled trials. 2,3 Recent evidence confirms that gabapentin and pregabalin

2019 Therapeutics Letter

15. Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness

Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Published on: July 31, 2017 (...) Project Number: RB1124-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of pre-operative administration of gabapentin to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of celecoxib to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of acetaminophen to reduce post

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

16. Gabapentin for Chronic Neuropathic Pain. (Abstract)

Gabapentin for Chronic Neuropathic Pain. Is gabapentin associated with pain relief in people with chronic neuropathic pain?Oral gabapentin (1200-3600 mg/d for 4-12 weeks) for patients with moderate or severe neuropathic pain from postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN) is associated with pain reduction of at least 50% in 14% to 17% more patients than placebo.

2018 JAMA

17. Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy

Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03749642 Recruitment Status : Recruiting First Posted : November 21, 2018

2018 Clinical Trials

18. A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis

A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

19. Gabapentin for Alcohol Withdrawal Syndrome

Gabapentin for Alcohol Withdrawal Syndrome Gabapentin for Alcohol Withdrawal Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Gabapentin for Alcohol Withdrawal Syndrome The safety and scientific (...) , and cravings is gabapentin. In clinical practice at Mayo Clinic gabapentin is used for this purpose. Due to the limited reports of the safety and efficacy of a protocol involving gabapentin for AWS, a study to compare gabapentin to symptom-triggered lorazepam will be completed. Condition or disease Intervention/treatment Phase Alcohol Withdrawal Syndrome Drug: Gabapentin Drug: Benzodiazepines Drug: Divalproex Sodium Phase 4 Detailed Description: The current "gold-standard" for the management of alcohol

2016 Clinical Trials

20. Gabapentin

Gabapentin Gabapentin - Wikipedia Gabapentin From Wikipedia, the free encyclopedia Gabapentin Clinical data Neurontin, others Synonyms CI-945; GOE-3450; DM-1796 (Gralise) / : : (Risk not ruled out) ( ) Legal status (Prescription only) (Prescription only) data 27–60% (inversely proportional to dose; a high fat meal also increases bioavailability) Less than 3% Not significantly metabolized 5 to 7 hours Identifiers 1-(aminomethyl)cyclohexaneacetic acid Y Y Y Y Y Y GBN ( , ) Chemical and physical (...) data C 9 H 17 N O 2 171.237 g/mol g·mol −1 3D model ( ) O=C(O)CC1(CN)CCCCC1 InChI=1S/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12) Y Key:UGJMXCAKCUNAIE-UHFFFAOYSA-N Y Gabapentin , sold under the brand name Neurontin among others, is an medication used to treat , , , and . It is recommended as one of a number of first-line medications for the treatment of neuropathic pain caused by , , and central neuropathic pain. About 15% of those given gabapentin for diabetic neuropathy

2012 Wikipedia